Placebo News and Research

RSS

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Active Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound Tasquinimod "TASQ".

18 Apr 2011

Patients with schizophrenia can benefit from L-lysine treatment

Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms.

18 Apr 2011

Probiotic may reduce rate of recurrent urinary tract infections in women

Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.

16 Apr 2011

Energy drinks with alcohol may increase risk of drinking

Energy drinks mixed with alcohol, such as Red Bull- and vodka, have become trendy. While this consumption has been implicated in risky drinking practices and associated accidents and injuries, there is little laboratory research on how the effects of this combination differ from those of drinking alcohol alone.

16 Apr 2011

Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis, today presented important efficacy data at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering Par Pharmaceutical Inc. not to make, use, sell, offer to sell, or import into the United States a generic version of sumatriptan/naproxen sodium that competes with Treximet sold by GlaxoSmithKline in the United States under an exclusive license from the Company.

15 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

The U.S. Food and Drug Administration today approved Actemra, given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children ages 2 years and older.

15 Apr 2011

New mixed-carb plus protein formulation more effective for female athletes

A "low-carb, mixed-carb" sports drink with added protein leads to prolonged endurance performance in trained female athletes, according to a study in the April issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Apr 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

Perampanel drug can effectively treat seizures in patients with epilepsy

A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug.

15 Apr 2011

FDA panel votes in favour of Sunitib (Sutent) for pancreatic tumors

Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.

12 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Sirolimus may help treat lymphangioleiomyomatosis in women

An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

African-American adults with CVD may benefit from 'sunshine vitamin'

In recent years supplementation with Vitamin D has been shown to reduce the risk of cardiovascular disease in people who are deficient in the vitamin.

12 Apr 2011

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

DURECT Corporation announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch.

12 Apr 2011

Placebo News and Research

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Patients with schizophrenia can benefit from L-lysine treatment

Probiotic may reduce rate of recurrent urinary tract infections in women

Energy drinks with alcohol may increase risk of drinking

Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

New mixed-carb plus protein formulation more effective for female athletes

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Perampanel drug can effectively treat seizures in patients with epilepsy

FDA panel votes in favour of Sunitib (Sutent) for pancreatic tumors

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Sirolimus may help treat lymphangioleiomyomatosis in women

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Laquinimod drug greatly reduces number of relapses in patients with MS

African-American adults with CVD may benefit from 'sunshine vitamin'

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News